Innoviva, GSK: EU Approves Label Update To Relvar Ellipta In Asthma Patients

(RTTNews) - Innoviva, Inc. (INVA) and GlaxoSmithKline plc (GSK, GSK.L) announced Thursday that the European Commission has approved a label update to Relvar Ellipta in patients with asthma.

The label update is for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting ß2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting ß2-agonist.

The updated marketing authorisation by the European Commission will be reflected in the label for Relvar Ellipta for countries in the European Union.

The company said the Type II variation regulatory approval has been supported by data from a non-inferiority lung function study, which demonstrated that patients with adequately controlled asthma were able to switch to the once-daily FF/VI 100/25, from the twice-daily Seretide Accuhaler (fluticasone propionate /salmeterol, FP/SAL) 250/50, without compromising their lung function. No new safety signals were identified and the adverse event data were consistent with the known safety profile for FF/VI established in patients with asthma.

Jonathan Sweeting, SVP and Head of Global Respiratory Franchise GSK, said: "Patients with asthma can continue to experience symptoms despite being adequately controlled and these symptoms can impact their lives. This label update gives doctors the option of switching appropriate patients from their current ICS/LABA to once-daily Relvar Ellipta."